Global Cefotaxime Sodium API Market Growth 2025-2031

Publication ID:

LPI01250905

Publication Date:

January 8, 2025

Pages:

122

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Cefotaxime Sodium API market size is predicted to grow from US$ 97 million in 2025 to US$ 92.7 million in 2031; it is expected to grow at a CAGR of -0.8% from 2025 to 2031.
Cefotaxime sodium is the sodium salt form of cefotaxime, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Cefotaxime sodium binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linking of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, cefotaxime sodium is more active against gram-negative bacteria and less active against gram-positive bacteria.
Market competition is intense. REYOUNG, Nectar Lifesciences, Medya Pharma, Sandoz, Kelun, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers. Top 5 manufacturers accountted for 57.98% market share in 2019.
The 鈥淐efotaxime Sodium API Industry Forecast鈥� looks at past sales and reviews total world Cefotaxime Sodium API sales in 2024, providing a comprehensive analysis by region and market sector of projected Cefotaxime Sodium API sales for 2025 through 2031. With Cefotaxime Sodium API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cefotaxime Sodium API industry.
This Insight Report provides a comprehensive analysis of the global Cefotaxime Sodium API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cefotaxime Sodium API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Cefotaxime Sodium API market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cefotaxime Sodium API and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cefotaxime Sodium API.
This report presents a comprehensive overview, market shares, and growth opportunities of Cefotaxime Sodium API market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
ChP
USP
EP
Segmentation by Application:
Single Injection
Compound Injection
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
REYOUNG
Nectar Lifesciences
Medya Pharma
Sandoz
Kelun
NCPC
Aurobindo Pharma
United Laboratories
Orchid Pharma
CSPC
Kopran
Covalent
ACS Dobfar
Dawnrays
Sterile India
Key Questions Addressed in this Report
What is the 10-year outlook for the global Cefotaxime Sodium API market?
What factors are driving Cefotaxime Sodium API market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Cefotaxime Sodium API market opportunities vary by end market size?
How does Cefotaxime Sodium API break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Cefotaxime Sodium API Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Cefotaxime Sodium API by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Cefotaxime Sodium API by Country/Region, 2020, 2024 & 2031
2.2 Cefotaxime Sodium API Segment by Type
2.2.1 ChP
2.2.2 USP
2.2.3 EP
2.3 Cefotaxime Sodium API Sales by Type
2.3.1 Global Cefotaxime Sodium API Sales Market Share by Type (2020-2025)
2.3.2 Global Cefotaxime Sodium API Revenue and Market Share by Type (2020-2025)
2.3.3 Global Cefotaxime Sodium API Sale Price by Type (2020-2025)
2.4 Cefotaxime Sodium API Segment by Application
2.4.1 Single Injection
2.4.2 Compound Injection
2.5 Cefotaxime Sodium API Sales by Application
2.5.1 Global Cefotaxime Sodium API Sale Market Share by Application (2020-2025)
2.5.2 Global Cefotaxime Sodium API Revenue and Market Share by Application (2020-2025)
2.5.3 Global Cefotaxime Sodium API Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Cefotaxime Sodium API Breakdown Data by Company
3.1.1 Global Cefotaxime Sodium API Annual Sales by Company (2020-2025)
3.1.2 Global Cefotaxime Sodium API Sales Market Share by Company (2020-2025)
3.2 Global Cefotaxime Sodium API Annual Revenue by Company (2020-2025)
3.2.1 Global Cefotaxime Sodium API Revenue by Company (2020-2025)
3.2.2 Global Cefotaxime Sodium API Revenue Market Share by Company (2020-2025)
3.3 Global Cefotaxime Sodium API Sale Price by Company
3.4 Key Manufacturers Cefotaxime Sodium API Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Cefotaxime Sodium API Product Location Distribution
3.4.2 Players Cefotaxime Sodium API Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Cefotaxime Sodium API by Geographic Region
4.1 World Historic Cefotaxime Sodium API Market Size by Geographic Region (2020-2025)
4.1.1 Global Cefotaxime Sodium API Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Cefotaxime Sodium API Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Cefotaxime Sodium API Market Size by Country/Region (2020-2025)
4.2.1 Global Cefotaxime Sodium API Annual Sales by Country/Region (2020-2025)
4.2.2 Global Cefotaxime Sodium API Annual Revenue by Country/Region (2020-2025)
4.3 Americas Cefotaxime Sodium API Sales Growth
4.4 APAC Cefotaxime Sodium API Sales Growth
4.5 Europe Cefotaxime Sodium API Sales Growth
4.6 Middle East & Africa Cefotaxime Sodium API Sales Growth
5 Americas
5.1 Americas Cefotaxime Sodium API Sales by Country
5.1.1 Americas Cefotaxime Sodium API Sales by Country (2020-2025)
5.1.2 Americas Cefotaxime Sodium API Revenue by Country (2020-2025)
5.2 Americas Cefotaxime Sodium API Sales by Type (2020-2025)
5.3 Americas Cefotaxime Sodium API Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Cefotaxime Sodium API Sales by Region
6.1.1 APAC Cefotaxime Sodium API Sales by Region (2020-2025)
6.1.2 APAC Cefotaxime Sodium API Revenue by Region (2020-2025)
6.2 APAC Cefotaxime Sodium API Sales by Type (2020-2025)
6.3 APAC Cefotaxime Sodium API Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Cefotaxime Sodium API by Country
7.1.1 Europe Cefotaxime Sodium API Sales by Country (2020-2025)
7.1.2 Europe Cefotaxime Sodium API Revenue by Country (2020-2025)
7.2 Europe Cefotaxime Sodium API Sales by Type (2020-2025)
7.3 Europe Cefotaxime Sodium API Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Cefotaxime Sodium API by Country
8.1.1 Middle East & Africa Cefotaxime Sodium API Sales by Country (2020-2025)
8.1.2 Middle East & Africa Cefotaxime Sodium API Revenue by Country (2020-2025)
8.2 Middle East & Africa Cefotaxime Sodium API Sales by Type (2020-2025)
8.3 Middle East & Africa Cefotaxime Sodium API Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Cefotaxime Sodium API
10.3 Manufacturing Process Analysis of Cefotaxime Sodium API
10.4 Industry Chain Structure of Cefotaxime Sodium API
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Cefotaxime Sodium API Distributors
11.3 Cefotaxime Sodium API Customer
12 World Forecast Review for Cefotaxime Sodium API by Geographic Region
12.1 Global Cefotaxime Sodium API Market Size Forecast by Region
12.1.1 Global Cefotaxime Sodium API Forecast by Region (2026-2031)
12.1.2 Global Cefotaxime Sodium API Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Cefotaxime Sodium API Forecast by Type (2026-2031)
12.7 Global Cefotaxime Sodium API Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 REYOUNG
13.1.1 REYOUNG Company Information
13.1.2 REYOUNG Cefotaxime Sodium API Product Portfolios and Specifications
13.1.3 REYOUNG Cefotaxime Sodium API Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 REYOUNG Main Business Overview
13.1.5 REYOUNG Latest Developments
13.2 Nectar Lifesciences
13.2.1 Nectar Lifesciences Company Information
13.2.2 Nectar Lifesciences Cefotaxime Sodium API Product Portfolios and Specifications
13.2.3 Nectar Lifesciences Cefotaxime Sodium API Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Nectar Lifesciences Main Business Overview
13.2.5 Nectar Lifesciences Latest Developments
13.3 Medya Pharma
13.3.1 Medya Pharma Company Information
13.3.2 Medya Pharma Cefotaxime Sodium API Product Portfolios and Specifications
13.3.3 Medya Pharma Cefotaxime Sodium API Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Medya Pharma Main Business Overview
13.3.5 Medya Pharma Latest Developments
13.4 Sandoz
13.4.1 Sandoz Company Information
13.4.2 Sandoz Cefotaxime Sodium API Product Portfolios and Specifications
13.4.3 Sandoz Cefotaxime Sodium API Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Sandoz Main Business Overview
13.4.5 Sandoz Latest Developments
13.5 Kelun
13.5.1 Kelun Company Information
13.5.2 Kelun Cefotaxime Sodium API Product Portfolios and Specifications
13.5.3 Kelun Cefotaxime Sodium API Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Kelun Main Business Overview
13.5.5 Kelun Latest Developments
13.6 NCPC
13.6.1 NCPC Company Information
13.6.2 NCPC Cefotaxime Sodium API Product Portfolios and Specifications
13.6.3 NCPC Cefotaxime Sodium API Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 NCPC Main Business Overview
13.6.5 NCPC Latest Developments
13.7 Aurobindo Pharma
13.7.1 Aurobindo Pharma Company Information
13.7.2 Aurobindo Pharma Cefotaxime Sodium API Product Portfolios and Specifications
13.7.3 Aurobindo Pharma Cefotaxime Sodium API Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Aurobindo Pharma Main Business Overview
13.7.5 Aurobindo Pharma Latest Developments
13.8 United Laboratories
13.8.1 United Laboratories Company Information
13.8.2 United Laboratories Cefotaxime Sodium API Product Portfolios and Specifications
13.8.3 United Laboratories Cefotaxime Sodium API Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 United Laboratories Main Business Overview
13.8.5 United Laboratories Latest Developments
13.9 Orchid Pharma
13.9.1 Orchid Pharma Company Information
13.9.2 Orchid Pharma Cefotaxime Sodium API Product Portfolios and Specifications
13.9.3 Orchid Pharma Cefotaxime Sodium API Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Orchid Pharma Main Business Overview
13.9.5 Orchid Pharma Latest Developments
13.10 CSPC
13.10.1 CSPC Company Information
13.10.2 CSPC Cefotaxime Sodium API Product Portfolios and Specifications
13.10.3 CSPC Cefotaxime Sodium API Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 CSPC Main Business Overview
13.10.5 CSPC Latest Developments
13.11 Kopran
13.11.1 Kopran Company Information
13.11.2 Kopran Cefotaxime Sodium API Product Portfolios and Specifications
13.11.3 Kopran Cefotaxime Sodium API Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Kopran Main Business Overview
13.11.5 Kopran Latest Developments
13.12 Covalent
13.12.1 Covalent Company Information
13.12.2 Covalent Cefotaxime Sodium API Product Portfolios and Specifications
13.12.3 Covalent Cefotaxime Sodium API Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Covalent Main Business Overview
13.12.5 Covalent Latest Developments
13.13 ACS Dobfar
13.13.1 ACS Dobfar Company Information
13.13.2 ACS Dobfar Cefotaxime Sodium API Product Portfolios and Specifications
13.13.3 ACS Dobfar Cefotaxime Sodium API Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 ACS Dobfar Main Business Overview
13.13.5 ACS Dobfar Latest Developments
13.14 Dawnrays
13.14.1 Dawnrays Company Information
13.14.2 Dawnrays Cefotaxime Sodium API Product Portfolios and Specifications
13.14.3 Dawnrays Cefotaxime Sodium API Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Dawnrays Main Business Overview
13.14.5 Dawnrays Latest Developments
13.15 Sterile India
13.15.1 Sterile India Company Information
13.15.2 Sterile India Cefotaxime Sodium API Product Portfolios and Specifications
13.15.3 Sterile India Cefotaxime Sodium API Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Sterile India Main Business Overview
13.15.5 Sterile India Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂